Addex Therapeutics and Perceptive Advisors establish Neurosterix with $63M investment for developing allosteric modulators for neurological disorders.

Addex Therapeutics and Perceptive Advisors launch Neurosterix with $63M investment. Neurosterix focuses on developing allosteric modulators to treat underserved neurological disorders, backed by a preclinical assets portfolio and allosteric modulator drug discovery technology platform. Perceptive Xontogeny Venture Fund II leads the funding, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.